Real-world Persistency, Effectiveness, and Safety Among Patients with NMOSD Treated with Inebilizumab (20250110)

Study identification

• EU PAS number:
  EUPAS1000000958
• Study ID:
  1000000958
• Official title and acronym:
  Real-world Persistency, Effectiveness, and Safety Among Patients with NMOSD Treated with Inebilizumab (20250110)
• DARWIN EU® study:
  No
• Study countries:
  United States
• Study description:
  No information provided.
• Study status:
  Ongoing

Study timelines

Date when funding contract was signed

Planned:22/04/2025

Actual:22/04/2025

Study start date

Planned:25/02/2026

Actual:25/02/2026

Data analysis start date

Planned:25/02/2026

Actual:25/02/2026

Date of interim report, if expected

Planned:20/03/2026

Date of final study report

Planned:10/04/2026

Regulatory

• Was the study required by a regulatory body?:
  No
• Is the study required by a Risk Management Plan (RMP)?:
  Not applicable